For decades, sterility testing for sterile product quality relied on incubator results that could only confirm contamination, not its absence. Parametric release changes this by allowing batch release based on documented evidence of compliance with critical sterilization parameters, assuring outcomes through effective process control and monitoring.

PIC/S Annex 17 establishes a regulatory framework that aligns with EU GMP requirements, emphasizing a modern, risk-based approach to pharmaceutical manufacturing. It is crucial for sterile medicinal product manufacturers to comprehend this Annex to enhance operational efficiency, ensure regulatory compliance, and safeguard patient safety.

Parametric Release:

Parametric release, as defined by PIC/S and EU GMP Annex 17, allows for the release of terminally sterilized product batches based on critical process parameter reviews instead of finished product sterility testing. It is part of Real Time Release Testing (RTRT), focusing solely on terminally sterilized products in final containers (e.g., vials, ampoules, prefilled syringes) using validated sterilization methods like moist heat, dry heat, or radiation.

Key parameters reviewed typically include:

When essential parameters meet validated limits, the batch can be released without awaiting 14-day sterility test results.

The Evolution of Annex 17:

The revised Annex 17, effective July 2018, expanded its focus beyond parametric release for terminally sterilized products to encompass broader real-time release testing (RTRT) principles. This change was driven by advancements in process analytical technology (PAT), Quality by Design (QbD), and quality risk management (QRM), and aligns with PIC/S PE 009-14, indicating a shift in regulatory perspectives.

Annex 17 provides a framework for manufacturers to adopt a scientifically sound, process-based methodology instead of routine sterility testing.

Core Requirements for Parametric Release

Implementing parametric release requires a comprehensive, integrated system of controls, as outlined in Annex 17, which specifies several critical elements that need to be established and documented.

1. Sterility Assurance Program

A sterility assurance program must encompass the identification and monitoring of critical process parameters, validation and control of the sterilization cycle, verification of container/closure integrity, control of bioburden, an environmental monitoring program, and segregation of sterilized from unsterilized materials.

2. Contamination Control Strategy (CCS)

The 2022 revision of PIC/S Annex 1 emphasizes the necessity of a Contamination Control Strategy (CCS) for sterile manufacturing, crucial for parametric release. CCS systematically manages contamination risks from microbial sources, endotoxins, and particulate matter. It includes at least 16 components such as facility design, personnel qualification, utility systems, and continuous improvement methods. For parametric release, CCS must ensure consistent control of microbial contamination risks throughout the manufacturing process.

3. Process Validation and Ongoing Control

Parametric release mandates thorough validation of the sterilization process, encompassing heat distribution studies, biological indicator challenge testing, F0 calculation for moist heat sterilization, and continuous monitoring to maintain validation. Any deviation from established parameters necessitates detailed investigation, as adverse trends cannot be mitigated by end-product testing.

4. Bioburden Monitoring

Bioburden, the microbial load prior to sterilization, is a crucial factor. Annex 17 mandates routine monitoring of bioburden in products, components, and the environment, as well as the establishment of alert and action limits. It is essential to understand microbial species and their resistance to sterilization methods, as high bioburden or resistant organisms can jeopardize sterilization effectiveness, regardless of physical parameter compliance.

5. Equipment and Facility Controls

Parametric release requires careful management of sterilizer calibration and maintenance, along with preventive maintenance programs. Additionally, computerized system validation for cycle control and data acquisition is essential, and any changes to equipment, processes, or components must be assessed for their impact on sterility assurance.

6. Personnel Training

Personnel engaged in parametric release need specific training on relevant principles, technologies, and procedures, including operators, quality control staff, and authorized individuals responsible for batch release.

7. Documentation and Batch Review

Parametric release emphasizes evaluating manufacturing documentation over laboratory records. The batch review requires assessing sterilization cycle data, bioburden results, container/closure integrity records, environmental monitoring data, deviations and investigations, and change control records. A batch can only be released after a thorough review of all critical parameters by an authorized individual.

Implementing Parametric Release: Practical Considerations

1. Assess Readiness

Manufacturers must evaluate several key factors before pursuing parametric release: the full validation of the sterilization process, consistent low and well-characterized bioburden, strict control of equipment and facilities, and the capability of the quality system to support real-time data review.

2. Develop a Comprehensive CCS

The CCS serves as the fundamental basis for parametric release, outlining the control of contamination sources and ensuring process parameters that guarantee sterility. It is a dynamic document, requiring regular reviews and updates in response to data trends and process enhancements.

3. Engage Regulators Early

Parametric release necessitates regulatory approval, usually requiring prior authorization in various jurisdictions. Early engagement with the competent authority is essential to comprehend requirements and expectations, particularly for PIC/S members, who should align with EU GMP Annex 17.

4. Invest in Data Integrity

Parametric release requires regulatory approval and prior authorization in different jurisdictions. Early interaction with the competent authority is crucial to understand the requirements and expectations, especially for PIC/S members, who must comply with EU GMP Annex 17.

5. Train the Organization

Moving from sterility testing to parametric release necessitates a cultural shift, requiring operators to grasp their process control roles, quality staff to be skilled in analyzing process data, and authorized personnel to be confident in releasing products without sterility test results.

Benefits of Parametric Release

• Reduced time to market is achieved by enabling product releases just days after manufacturing instead of the previous weeks-long timeframe.
• Lower inventory costs result in reduced holding time for quarantine.
• Whole-batch evaluation is emphasized as a superior method to limited sample testing for ensuring greater product quality assurance.
• Regulatory alignment is consistent with modern risk-based GMP expectations, while sustainability efforts focus on reducing laboratory consumables and waste.

For high-volume sterile products, the time-to-release advantage enhances supply chain efficiency and patient access.

Global Adoption and Regulatory Status

PIC/S Annex 17 aligns with the EU GMP Guide Annex 17, effective since December 2018, and encourages PIC/S Participating Authorities to incorporate it into their GMP guides.

In practice:

Manufacturers should always verify specific requirements with their local regulatory authority.

Zenovel offers GMP consulting services aimed at assisting pharmaceutical manufacturers with Annex 17 parametric release and effective Contamination Control Strategies. Leveraging expertise in sterile manufacturing and regulatory compliance, Zenovel supports clients from readiness assessments to regulatory approvals, enhancing batch release confidence and efficiency.